Biotech Values

[onco_investor]

ONCY Phase II REO+Low Dosage Radiation target patients that had previously failed to respond to treatments some of which were radiation.

Note the strong responders with what is considered just pallative radiation dosages.

http://www.integratir.com/newsrelease.asp?news=2130956011&ticker=T.ONC&lang=EN&ny=on

The trial is an open-label, single-arm, multi-centre Phase II study of REOLYSIN® delivered via intratumoural injection to patients during treatment with low-dose radiotherapy. Up to 40 evaluable patients, including approximately 20 patients with head and neck and esophageal cancers, and approximately 20 patients with other advanced cancers, will be treated with two intratumoural doses of REOLYSIN® at 1x1010 TCID50 with a constant localized radiation dose of 20 Gy in five consecutive daily fractions. Eligible patients include those who have been diagnosed with advanced or metastatic cancers including head, neck and esophageal tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

Other clinical trials being run by ONCY are listed at

http://www.integratir.com/newsrelease.asp?news=2130956011&ticker=T.ONC&lang=EN&ny=on